Colorado HIV Surveillance Quarterly Report 4th Quarter 2013

What's in this report?

| HIV in Colorado: An Overview | 1 |
|---------------------------------|----|
| How HIV/AIDS Surveillance Works | 2 |
| Definitions | 3 |
| Statistics | |
| New HIV Cases | 4 |
| People Living with HIV | 9 |
| Acknowledgements | 17 |

Publication Schedule: This report reflects events occurring through December 31, 2013, and reported by December 31, 2013, unless otherwise stated. Reports are published twice a year.

To receive this report via e-mail, send an e-mail request to: cdphe_stihivdatarequest@state.co.us

Electronic versions of this and other HIV-related reports are available on the internet at:

http://www.colorado.gov/cs/Satellite/CDPHE-DCEED/CBON/1251621434445

HIV in Colorado: An Overview

- There has been a 22% decrease in HIV incidence in the past year, from 388 new HIV diagnoses in 2012 to 302 in 2013.
- Nearly one-third of the 1,886 adults and adolescents diagnosed with HIV infection in the past 5 years (2009-2013) developed HIV infection Stage 3 (AIDS) within 1 year, indicating that they received HIV testing late in the course of the infection.
- By the end of 2013, there were an estimated 12,623 people living with HIV or AIDS (PLWHA) in Colorado. This number includes Colorado residents diagnosed with HIV and PLWHA who have moved into Colorado. Over 5,930 people with HIV disease in Colorado have died.
- Compared to all persons living with HIV, newly diagnosed Colorado HIV cases included more people of color, fewer injection drug users (IDU) and more people reporting heterosexual risk.



Colorado Department of Public Health and Environment



HOW HIV/AIDS SURVEILLANCE WORKS IN COLORADO

Health care providers, laboratories, and local health departments are required by law to report HIV- and AIDS-related information according to the requirements listed below. Identifying and reporting new HIV cases helps state and local health departments develop programs that reduce the spread of HIV. Case reporting also helps assure that people living with HIV receive treatment as early as possible, and that partners who have been exposed to the virus receive HIV testing. Federal funding for HIV prevention and treatment is based on case counts. Our state benefits the most when HIV surveillance is complete, accurate and timely. Copies of the case report form can be found at the Colorado Department of Public Health and Environment website: http://www.colorado.gov/cs/Satellite/CDPHE-DCEED/CBON/1251621400997. Fax the completed form to: 303-782-5393

For federal funding purposes, all states and territories count HIV/AIDS cases in the same manner. An individual gets counted as an HIV case in the county in which he/she is residing at the time of his/her initial HIV diagnosis (not including a diagnosis made from an anonymous test). Once that person progresses to AIDS, he/she is counted as an AIDS case in the county in which he/she is residing at the time of his/her AIDS diagnosis. An AIDS case is no longer counted as an HIV case. States are continually working with each other to ensure that cases are counted in only one state. Once a person is diagnosed with AIDS, he/she remains an AIDS case even if his/her health later improves. Within Colorado, county-level case counts can go down if we learn that a person's earliest diagnosis of HIV or AIDS actually occurred while he/she resided in another state or county. Also, a county's HIV case count can go down over time if their HIV cases progress to AIDS while residing outside the county.

For epidemiologic purposes, it is helpful to evaluate all cases of HIV and AIDS as part of one combined group: people who have been diagnosed with HIV disease. For this report, geographic assignment of a new HIV case is based on residence at the time of a person's initial HIV diagnosis, regardless of whether he/she later progressed to AIDS. Living cases are presumed to be in the same place they resided when their most recent diagnosis of HIV or AIDS occurred.

HIV/AIDS Reporting Requirements:

| REPORTING | ITEM TO REPORT | TIMELINE | TO WHOM |
|--------------------------|---|----------|----------------------------------|
| Health care providers | HIV or AIDS diagnosis | 7 days | State or local health department |
| Health care facilities | HIV or AIDS diagnosis | 7 days | State or local health department |
| Laboratories | Any test result that indicates HIV infection, including any undetectable HIV viral load and HIV genotype testing; All CD4 counts regardless of value; All HIV viral load results; | 7 days | State health department |
| Local health departments | HIV and AIDS | 7 days | State health department |

DEFINITIONS

AIDS: Acquired Immune Deficiency Syndrome. An advanced stage of HIV disease which is defined by the existence of certain opportunistic illnesses or other clinical outcomes. The presence of AIDS usually suggests that a person has been HIV-positive for many years.

Case: A person with HIV disease who has been diagnosed and reported to the health department while living in Colorado. This report does not describe the results of anonymous HIV testing.

Case Rate: The number of reported cases divided by the number of people residing in a given area and presumed to be at risk for disease, based on population estimates. In this report, rates are described as cases per 100,000 residents.

CD4 Count: The concentration of a certain type of white blood cell circulating within a person's body. CD4 count provides a good indication of a patient's stage of HIV illness.

Confidence Interval (CI): A range of values within which the true value is likely to exist. In this report, we use 95% confidence intervals to describe the reliability of disease rates.

Cumulative HIV cases: The total number of HIV cases ever reported, as of a specific point in time. Cumulative cases include people who are both living and deceased.

Exposure category: The manner in which a case was most likely to have been infected by HIV, based on reported risk behaviors. Categories are arranged in a hierarchy. A case can only be assigned to one exposure category at any given time.

Foreign-born: This term is used to describe people born outside the United States. If information about country of birth is missing, a case is presumed to be foreign-born.

Gender: A person's sex at birth, either male or female.

HIV: Human Immunodeficiency Virus. The virus that causes HIV disease, including AIDS.

HIV/AIDS deaths: Deaths caused by HIV or AIDS. We use death certificate information to determine whether HIV or AIDS was a contributing factor in a patient's death.

HIV diagnosis date: The earliest, documented date when a person was diagnosed with HIV disease, with or without AIDS.

HIV Incidence: The number of people newly infected with HIV during a specified time period, often a calendar year. We can only estimate HIV incidence. This report does not include estimates of HIV incidence.

HIV Prevalence: The total number of people living with HIV disease at a specific point in time. We can only estimate HIV prevalence. This report does not include estimates of HIV prevalence.

HIV Surveillance: The ongoing and systematic collection, evaluation and dissemination of population-based information about people diagnosed with HIV disease.


Late HIV Diagnosis: This describes the event in which a case is diagnosed with AIDS within 12 months of HIV diagnosis. A late HIV diagnosis indicates that a person was probably not getting routinely tested for HIV before the diagnosis occurred.

Living HIV Case: A case of HIV disease that has been diagnosed while living in Colorado, reported to the health department, and is presumed living at a specific point in time. A living HIV case can also be described as a prevalent HIV case.

New HIV Case: A newly diagnosed case of HIV disease, with or without AIDS, that has been diagnosed while living in Colorado.

Reporting delay: This refers to the length of time between when a case is diagnosed and when the case is reported to the health department. In Colorado, most cases are reported within 6 months.

Viral Load: This is the concentration of viral copies circulating within a person's body. Viral load is a good indication of whether a person is receiving effective treatment for HIV disease.



STATISTICS: NEW HIV CASES

| Newly Diagnosed Cases of HIV Disease Diagnoses | Table 1. New HIV Cases | | | | | | | | | Late HIV |
|--|-------------------------------|------|----------|---------|----------|----------|--------|------|------|------------------------|
| Total No. No. </th <th></th> <th>Nev</th> <th>vly Diag</th> <th>nosed C</th> <th>Cases of</th> <th>HIV Dise</th> <th>ease</th> <th></th> <th></th> <th>Diagnoses</th> | | Nev | vly Diag | nosed C | Cases of | HIV Dise | ease | | | Diagnoses |
| Total 388 430 378 388 302 186 100 7.5 33% Gender Male 339 370 325 328 261 1623 86% 12.8 33% Female 49 60 53 60 41 263 14% 2.1 27% Age at HIV Diagnosis Under 13 years 10 11 7 7 6 4 27 1% 0.6 4% 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 </th <th>Year of HIV diagnosis</th> <th>2009</th> <th>2010</th> <th>2011</th> <th>2012</th> <th>2013</th> <th>2009-2</th> <th>2013</th> <th></th> <th>2009-2013[†]</th> | Year of HIV diagnosis | 2009 | 2010 | 2011 | 2012 | 2013 | 2009-2 | 2013 | | 2009-2013 [†] |
| Gender Male 339 370 325 328 261 1623 86% 12.8 33% Female 49 60 53 60 41 263 14% 2.1 27% Age at HIV Diagnosis Under 13 years 3 7 7 6 4 27 1% 0.6 4% 13-19 years 10 11 7 7 4 39 2% 1.6 8% 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 | | No. | No. | No. | No. | No. | No. | % | Rate | % |
| Male Female 339 370 325 328 261 1623 86% 12.8 33% Female 49 60 53 60 41 263 14% 2.1 27% Age at HIV Diagnosis Under 13 years 3 7 7 6 4 27 1% 0.6 4% 13-19 years 10 11 7 7 4 39 22 1.6 8% 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 1.5 67% 70 years and over 4 2 5 2 1 <th>Total</th> <th>388</th> <th>430</th> <th>378</th> <th>388</th> <th>302</th> <th>1886</th> <th>100</th> <th>7.5</th> <th>33%</th> | Total | 388 | 430 | 378 | 388 | 302 | 1886 | 100 | 7.5 | 33% |
| Female 49 60 53 60 41 263 14% 2.1 27% Age at HIV Diagnosis Under 13 years 3 7 7 6 4 27 1% 0.6 4% 13-19 years 10 11 7 7 4 39 2% 1.6 8% 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% 8 10 6 6 8 3 2 5 <td>Gender</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> | Gender | | | | | | | | | |
| March Marc | Male | 339 | 370 | 325 | 328 | 261 | 1623 | 86% | 12.8 | 33% |
| Under 13 years | Female | 49 | 60 | 53 | 60 | 41 | 263 | 14% | 2.1 | 27% |
| 13-19 years 10 11 7 7 7 4 39 2% 1.6 8% 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 2 5 2 1 14 14 1% 0.8 64% Eac and Hispanic Origin White, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 10 12 17 7.3 26% Multiple Race Asea (MSM) 254 267 241 244 181 1187 73% 17% Exposure Category - Male only 11 10 11 7 9 9 48 33% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 5% 51% Pediatric* 2 4 5 2 9 5 2 20 8% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 2 9 5 5 2 20 8% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 2 9 5 5 2 20 8% 52% Exposure Category - Female Injection Drug Use (IDU) 3 45 25 35 25 163 62% 52% Exposure Category - Female Injection Drug Use (IDU) 4 2 2 9 9 5 2 2 0 8% 52% Exposure Category - Female Injection Drug Use (IDU) 4 2 2 9 9 5 2 2 0 8% 52% Exposure Category - Female Injection Drug Use (IDU) 4 2 2 9 9 5 2 2 0 8% 52% Exposure Category - Female Injection Drug Use (IDU) 4 3 2 2 4 4 5 2 2 2 2 2 8% 52% Exposure Category - Female Injection Drug Use (IDU) 4 3 2 2 4 4 5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 | Age at HIV Diagnosis | | | | | | | | | |
| 20-29 years 134 132 113 144 99 622 33% 17.1 19% 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% 60-69 years 70 years and over 4 2 5 2 1 14 1% 0.8 64% 60-69 years 70 years and over 70 years and over 70 years and over 70 years and over 8 25 2 1 14 1% 0.8 64% 70 years and over 70 years an | Under 13 years | 3 | 7 | 7 | 6 | 4 | 27 | 1% | 0.6 | 4% |
| 30-39 years 98 108 102 112 87 507 27% 14.1 32% 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 <td< td=""><td>13-19 years</td><td>10</td><td>11</td><td>7</td><td>7</td><td>4</td><td>39</td><td>2%</td><td>1.6</td><td>8%</td></td<> | 13-19 years | 10 | 11 | 7 | 7 | 4 | 39 | 2% | 1.6 | 8% |
| 40-49 years 92 103 91 81 72 439 23% 12.0 46% 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 | 20-29 years | 134 | 132 | 113 | 144 | 99 | 622 | 33% | 17.1 | 19% |
| 50-59 years 35 53 46 28 25 187 10% 5.3 46% 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 2 2 | 30-39 years | 98 | 108 | 102 | 112 | 87 | 507 | 27% | 14.1 | 32% |
| 60-69 years 12 14 7 8 10 51 3% 1.5 67% 70 years and over 4 2 5 2 1 14 1% 0.8 64% Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 6 8 38 2% 5.1 34% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 11% 7.3 2.5 1 2 1 2 1 2 < | 40-49 years | 92 | 103 | 91 | 81 | 72 | 439 | 23% | 12.0 | 46% |
| Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU <td>50-59 years</td> <td>35</td> <td>53</td> <td>46</td> <td>28</td> <td>25</td> <td>187</td> <td>10%</td> <td>5.3</td> <td>46%</td> | 50-59 years | 35 | 53 | 46 | 28 | 25 | 187 | 10% | 5.3 | 46% |
| Race and Hispanic Origin White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only 8 267 241 244 181 1187 73% 17% Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug | 60-69 years | 12 | 14 | 7 | 8 | 10 | 51 | 3% | 1.5 | 67% |
| White, not Hispanic 197 231 204 193 150 975 52% 5.4 31% Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only Whate-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 20% MSM & IDU 19 31 <td>70 years and over</td> <td>4</td> <td>2</td> <td>5</td> <td>2</td> <td>1</td> <td>14</td> <td>1%</td> <td>0.8</td> <td>64%</td> | 70 years and over | 4 | 2 | 5 | 2 | 1 | 14 | 1% | 0.8 | 64% |
| Black, not Hispanic 59 91 56 68 52 326 17% 31.6 25% Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only 8 267 241 244 181 1187 73% 17% Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 51% Pediatric* 2 4 5 2 | Race and Hispanic Origin | | | | | | | | | |
| Hispanic (All Races) 117 90 106 114 89 516 27% 10.3 40% Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only White Pace 8 267 241 244 181 1187 73% 17% Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 | White, not Hispanic | 197 | 231 | 204 | 193 | 150 | 975 | 52% | 5.4 | 31% |
| Asian/Pacific Islander 8 10 6 6 8 38 2% 5.1 34% Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only Wale-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophilia 0 0 0 <td< td=""><td>Black, not Hispanic</td><td>59</td><td>91</td><td>56</td><td>68</td><td>52</td><td>326</td><td>17%</td><td>31.6</td><td>25%</td></td<> | Black, not Hispanic | 59 | 91 | 56 | 68 | 52 | 326 | 17% | 31.6 | 25% |
| Amer. Indian/Alaska Native 4 3 5 5 2 19 1% 7.3 26% Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only Exposure Category - Male only Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0 0 52% | Hispanic (All Races) | 117 | 90 | 106 | 114 | 89 | 516 | 27% | 10.3 | 40% |
| Multiple Race 3 5 1 2 1 12 1% 17% Exposure Category - Male only Wale-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0 0 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Hete | Asian/Pacific Islander | 8 | 10 | 6 | 6 | 8 | 38 | 2% | 5.1 | 34% |
| Exposure Category - Male only Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0 0 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% - | Amer. Indian/Alaska Native | 4 | 3 | 5 | 5 | 2 | 19 | 1% | 7.3 | 26% |
| Male-male sex (MSM) 254 267 241 244 181 1187 73% 31% Injection Drug Use (IDU) 11 10 11 7 9 48 3% 40% MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0 0 0 0 0 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% < | Multiple Race | 3 | 5 | 1 | 2 | 1 | 12 | 1% | | 17% |
| Injection Drug Use (IDU) | Exposure Category - Male only | / | | | | | | | | |
| MSM & IDU 19 31 21 23 5 99 6% 20% Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0% No Identified Risk/Other 36 30 34 40 48 188 12% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0 0% | Male-male sex (MSM) | 254 | 267 | 241 | 244 | 181 | 1187 | 73% | | 31% |
| Heterosexual contact 17 28 13 12 15 85 5% 51% Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0% No Identified Risk/Other 36 30 34 40 48 188 12% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | Injection Drug Use (IDU) | 11 | 10 | 11 | 7 | 9 | 48 | 3% | | 40% |
| Pediatric* 2 4 5 2 3 16 1% 6% Transfusion/Hemophiliac 0 0 0 0 0 0 0% No Identified Risk/Other 36 30 34 40 48 188 12% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | MSM & IDU | 19 | 31 | 21 | 23 | 5 | 99 | 6% | | 20% |
| Transfusion/Hemophiliac 0 0 0 0 0 0 0 0% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0% | Heterosexual contact | 17 | 28 | 13 | 12 | 15 | 85 | 5% | | 51% |
| No Identified Risk/Other 36 30 34 40 48 188 12% 52% Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | Pediatric* | 2 | 4 | 5 | 2 | 3 | 16 | 1% | | 6% |
| Exposure Category - Female Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | Transfusion/Hemophiliac | 0 | 0 | 0 | 0 | 0 | 0 | 0% | | |
| Injection Drug Use (IDU) 2 2 9 5 2 20 8% 35% Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | No Identified Risk/Other | 36 | 30 | 34 | 40 | 48 | 188 | 12% | | 52% |
| Heterosexual contact 33 45 25 35 25 163 62% 24% Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0% | Exposure Category - Female | | | | | | | | | |
| Pediatric* 1 3 2 4 1 11 4% 0% Transfusion/Hemophilia 0 0 0 0 0 0 0 0% | | 2 | 2 | 9 | 5 | 2 | 20 | 8% | | 35% |
| Transfusion/Hemophilia 0 0 0 0 0 0 0% | Heterosexual contact | 33 | 45 | 25 | 35 | 25 | 163 | 62% | | 24% |
| | Pediatric [*] | 1 | 3 | 2 | 4 | 1 | 11 | 4% | | 0% |
| No Identified Risk/Other 13 10 17 16 13 69 26% 35% | Transfusion/Hemophilia | 0 | 0 | 0 | 0 | 0 | 0 | 0% | | |
| | No Identified Risk/Other | 13 | 10 | 17 | 16 | 13 | 69 | 26% | | 35% |

Due to delays in reporting, data from recent years are incomplete.

[†]Late HIV diagnoses based on new HIV cases diagnosed between 2009 and 2013.

 $^{^{\}ast}$ Pediatric cases are individuals under age 13 years at the time of HIV or AIDS diagnosis.

^{‡ 2008-2012} population estimate used in calculating the rates

STATISTICS: NEW HIV CASES (continued)

Table 1b. New HIV Cases by Foreign-Born Status and Other Select Characteristics, 2009-2013


Proportion of Cases with Select Characteristic at HIV Diagnosis

| Characteristic: | Male | Age > 34 years | MSM | Hetero- sexual | Late HIV Diagnosis | Live in Denver TGA* | То | tal |
|-------------------------------|------|-------------------|-----|-------------------|-----------------------|---------------------------|------|------|
| | % | % | % | % | % | % | No. | % |
| U.SBorn | | | | | | | | |
| White | 92% | 54% | 79% | 7% | 31% | 57% | 957 | 51% |
| Black | 79% | 40% | 59% | 18% | 22% | 15% | 219 | 12% |
| Hispanic (All Races) | 90% | 37% | 72% | 8% | 35% | 25% | 382 | 20% |
| Asian/Pacific Islander | 80% | 27% | 80% | 20% | 20% | 1% | 15 | 1% |
| American Indian/Alaska Native | 53% | 68% | 21% | 47% | 26% | 1% | 19 | 1% |
| Multiple Race | 92% | 33% | 83% | 8% | 17% | 1% | 12 | 1% |
| Total | 89% | 48% | 74% | 9% | 31% | 70% | 1604 | 100% |
| Foreign-Born | | | | | | | | |
| White | 89% | 28% | 56% | 6% | 39% | 6% | 18 | 1% |
| Black | 39% | 50% | 2% | 60% | 32% | 38% | 107 | 6% |
| Hispanic (All Races) | 87% | 49% | 58% | 16% | 54% | 48% | 134 | 7% |
| Asian/Pacific Islander | 74% | 57% | 35% | 43% | 43% | 8% | 23 | 1% |
| Total | 86% | 49% | 35% | 34% | 44% | 75% | 282 | 100% |

^{*}Most recent data available for county of residence is the 6-county Denver Transitional Grant Area (TGA) which includes Adams, Arapahoe, Broomfield, Denver, Douglas, and Jefferson counties.

Presumed Colorado residence based on most recent data available. No exclusions based on HIV lab tests.

Late HIV diagnoses based on new HIV cases diagnosed between 2009 and 2013.



STATISTICS: NEW HIV CASES (continued)

Table 1c. First CD4 Test *Results among New HIV Cases, 2009-2013

| | | Stage | of Infection | ո at HIV Diaչ | gnosis | | | | |
|----------------------------|--------------|-------|---------------|---------------|--------|---------------------|----------------------|----------|----------------|
| | | (amo | ng cases with | n CD4 informa | ation) | Median CD4 Count | Cases wit Informa | | Total Cases |
| CD4 coun | t, cells/μL: | ≥ 500 | 350-499 | 200-349 | < 200 | | | | |
| | | % | % | % | % | cells/μL | No. % | of Total | No. |
| Total | | 26% | 22% | 22% | 30% | 337 | 1,596 | 85% | 1,886 |
| Gender | | | | | | | | | |
| Male | | 25% | 22% | 22% | 31% | 334 | 1,383 | 85% | 1,623 |
| Female | | 30% | 22% | 22% | 26% | 377 | 213 | 81% | 263 |
| Age at HIV Diagnosis | 3 | | | | | | | | |
| < 13 | | 61% | 28% | 11% | 0% | 733 | 18 | 67% | 27 |
| 13-24 | | 32% | 31% | 24% | 13% | 420 | 262 | 82% | 320 |
| 25-34 | | 32% | 25% | 23% | 20% | 388 | 521 | 82% | 637 |
| 35-44 | | 21% | 17% | 23% | 39% | 266 | 381 | 86% | 443 |
| 45-54 | | 17% | 19% | 19% | 45% | 220 | 299 | 91% | 329 |
| 55+ | | 16% | 15% | 15% | 54% | 165 | 115 | 88% | 130 |
| Race and Hispanic O | rigin | | | | | | | | |
| White, not Hispani | С | 28% | 24% | 19% | 29% | 353 | 833 | 85% | 975 |
| Black, not Hispanic | | 26% | 26% | 25% | 23% | 357 | 247 | 76% | 326 |
| Hispanic (All Races |) | 21% | 18% | 25% | 36% | 286 | 462 | 90% | 516 |
| Asian/Pacific Island | ler | 22% | 19% | 25% | 34% | 317 | 32 | 84% | 38 |
| Amer. Indian/Alask | a Native | 15% | 23% | 23% | 39% | 268 | 13 | 68% | 19 |
| Multiple Race | | 45% | 11% | 22% | 22% | 455 | 9 | 75% | 12 |
| Exposure Category b | y Gender | | | | | | | | |
| Male only: | | | | | | | | | |
| Male-male sex (MS | SM) | 26% | 24% | 23% | 27% | 350 | 1,029 | 87% | 1,187 |
| Injection Drug Use | (IDU) | 26% | 23% | 14% | 37% | 331 | 43 | 90% | 48 |
| MSM & IDU | | 46% | 19% | 22% | 13% | 473 | 86 | 87% | 99 |
| Heterosexual conta | act | 12% | 13% | 22% | 53% | 192 | 68 | 80% | 85 |
| Pediatric [‡] | | 50% | 40% | 10% | 0% | 589 | 10 | 63% | 16 |
| Transfusion/Hemo | philiac | | | | | | 0 | | 0 |
| No Identified Risk/ | Other | 10% | 14% | 19% | 57% | 164 | 147 | 78% | 188 |
| Female only: | | | | | | | | | |
| Injection Drug Us | se (IDU) | 36% | 16% | 11% | 37% | 430 | 19 | 95% | 20 |
| Heterosexual cor | ntact | 32% | 27% | 17% | 24% | 400 | 132 | 81% | 163 |
| Pediatric | | 75% | 12% | 13% | 0% | 786 | 8 | 73% | 11 |
| Transfusion/Hem | ophiliac | | | | | | 0 | | 0 |
| No Identified Risl | - | 17% | 11% | 37% | 35% | 253 | 54 | 78% | 69 |

[†]Among Males, the median days between first CD4 test date and HIV diagnosis date is 7 days. For 92% percent of Males, the first CD4 test date was no more than 90 days from HIV diagnosis date. Among Females, the median days between first CD4 test date and HIV diagnosis date is 13 days. For 92% percent of Females, the first CD4 test date was no more than 90 days from HIV diagnosis date. All first CD4 test dates were within 1 year of HIV diagnosis dates.

^{*} Pediatric cases are individuals under age 13 years at the time of HIV diagnosis.




Table 2. People Living with HIV Disease as of December 31, 2013

| | HIV | (not AII | OS) | | AIDS | | All Case | All Cases of HIV Disease | | | |
|------------------------------------|-------|----------|------|-------|------|------|----------|--------------------------|---------------|--|--|
| | No. | % | Rate | No. | % | Rate | | % | Rate † | | |
| Total | 6,883 | 100% | 133 | 5,740 | 100% | 111 | 12,623 | 100% | 244 | | |
| Gender | | | | | | | | | | | |
| Male | 6,055 | 88% | 233 | 5,067 | 88% | 195 | 11,122 | 88% | 427 | | |
| Female | 828 | 12% | 32 | 673 | 12% | 26 | 1,501 | 12% | 58 | | |
| Age in Years (at end of 2013) | | | | | | | | | | | |
| < 13 | 21 | 0.3% | 4 | 4 | 0.1% | 1 | 25 | 0.2% | 5 | | |
| 13-24 | 562 | 8% | 75 | 209 | 4% | 28 | 771 | 6% | 103 | | |
| 25-34 | 1,130 | 16% | 156 | 770 | 13% | 106 | 1,900 | 15% | 263 | | |
| 35-44 | 1,765 | 26% | 248 | 1,892 | 33% | 266 | 3,657 | 29% | 514 | | |
| 45-54 | 2,214 | 32% | 306 | 1,958 | 34% | 271 | 4,172 | 33% | 576 | | |
| 55+ | 942 | 14% | 185 | 753 | 13% | 148 | 1,695 | 13% | 333 | | |
| Race and Hispanic Origin | | | | | | | | | | | |
| White, not Hispanic | 4,546 | 66% | 126 | 3,385 | 59% | 94 | 7,931 | 63% | 220 | | |
| Black, not Hispanic | 1,014 | 15% | 509 | 935 | 16% | 470 | 1,949 | 15% | 979 | | |
| Hispanic (All Races) | 1,123 | 16% | 103 | 1,272 | 22% | 117 | 2,395 | 19% | 220 | | |
| Asian/Pacific Islander | 75 | 1% | 49 | 58 | 1% | 38 | 133 | 1% | 87 | | |
| Amer. Indian/Alaska Native | 42 | 1% | 127 | 50 | 1% | 151 | 92 | 1% | 279 | | |
| Multiple Race/Unknown | 83 | 1% | | 40 | 1% | | 123 | 1% | | | |
| Exposure Category by Gender | | | | | | | | | | | |
| Male only | | | | | | | | | | | |
| Male-male sex (MSM) | 4,506 | 74% | | 3,600 | 71% | | 8,106 | 73% | | | |
| Injection Drug Use (IDU) | 281 | 5% | | 328 | 6% | | 609 | 5% | | | |
| MSM & IDU | 524 | 9% | | 519 | 10% | | 1,043 | 9% | | | |
| Heterosexual contact | 187 | 3% | | 274 | 5% | | 461 | 4% | | | |
| Pediatric [*] | 33 | 1% | | 16 | 0.3% | | 49 | 0.4% | | | |
| Transfusion/Hemophiliac | 7 | 0.1% | | 24 | 0.5% | | 31 | 0.3% | | | |
| No Identified Risk/Other | 517 | 9% | | 306 | 6% | | 823 | 7% | | | |
| Female only | | | | | | | | | | | |
| Injection Drug Use (IDU) | 140 | 17% | | 146 | 22% | | 286 | 19% | | | |
| Heterosexual contact | 465 | 56% | | 390 | 58% | | 855 | 57% | | | |
| Pediatric | 35 | 4% | | 7 | 1% | | 42 | 3% | | | |
| Transfusion/Hemophiliac | 3 | 0.4% | | 6 | 1% | | 9 | 1% | | | |
| No Identified Risk/Other | 185 | 22% | | 124 | 18% | | 309 | 21% | | | |

^{*}Due to delays in reporting, data from recent years are incomplete.

Presumed Colorado residence based on most recent data available. No exclusions based on HIV lab tests.

[†] 2012 Census population estimate used in calculating the rates.

[^] Pediatric cases are individuals under age 13 years at the time of HIV or AIDS diagnosis.

Table 3. People Living with HIV Disease as of December 31, 2013

| | Wh | ite | Bla | ıck | All His | spanic | Asia Pac Islan | ific | Amer India Alas Nat | an/ ska | Multi Unkn | • |
|--------------------------|------|------|------|------|---------|--------|----------------------|------|------------------------------|------------|---------------|-----|
| Exposure Category | No. | % | No. | % | No. | % | No. | % | No. | % | No. | % |
| Males: | | | | | | | | | | | | |
| Male-male sex (MSM) | 5720 | 78% | 778 | 55% | 1441 | 69% | 66 | 62% | 38 | 58% | 63 | 58% |
| Injection Drug Use (IDU) | 297 | 4% | 141 | 10% | 148 | 7% | 10 | 9% | 6 | 9% | 7 | 6% |
| MSM & IDU | 760 | 10% | 99 | 7% | 161 | 8% | 5 | 5% | 15 | 23% | 3 | 3% |
| Heterosexual contact | 119 | 2% | 222 | 16% | 102 | 5% | 13 | 12% | 2 | 3% | 3 | 3% |
| Pediatric [*] | 18 | 0.2% | 24 | 2% | 7 | 0.3% | 0 | 0% | 0 | 0% | 0 | 0% |
| Transfusion/Hemophiliac | 24 | 0.3% | 4 | 0.3% | 3 | 0.1% | 0 | 0% | 0 | 0% | 0 | 0% |
| No Identified Risk/Other | 389 | 5% | 159 | 11% | 225 | 11% | 12 | 11% | 5 | 8% | 33 | 30% |
| Total Males | 7327 | | 1427 | | 2087 | | 106 | | 66 | | 109 | |
| Exposure Category | | | | | | | | | | | | |
| Females: | | | | | | | | | | | | |
| Injection Drug Use (IDU) | 157 | 26% | 64 | 12% | 55 | 18% | 0 | 0% | 8 | 31% | 2 | 14% |
| Heterosexual contact | 314 | 52% | 337 | 65% | 167 | 54% | 20 | 74% | 13 | 50% | 4 | 29% |
| Pediatric [^] | 11 | 2% | 24 | 5% | 5 | 2% | 1 | 4% | 0 | 0% | 1 | 7% |
| Transfusion/Hemophiliac | 5 | 1% | 1 | 0.2% | 3 | 1% | 0 | 0% | 0 | 0% | 0 | 0% |
| No Identified Risk/Other | 117 | 19% | 96 | 18% | 78 | 25% | 6 | 22% | 5 | 19% | 7 | 50% |
| Total Females | 604 | | 522 | | 308 | | 27 | | 26 | | 14 | |

[^] Pediatric cases are individuals under age 13 years at the time of HIV or AIDS diagnosis.

Presumed Colorado residence based on most recent data available. No exclusions based on HIV lab tests.

Figure 4. Living HIV Case Rates by Race/Ethnicity and Gender, Colorado, as of December 31, 2013 ■ Male ■ Female **Cases per 100,000** I White Black Hispanic Asian/PI AI/AN

Table 4. HIV Diagnoses by Health Statistics Region (HSR) and County

Newly Diagnosed Cases of HIV Disease

| Year of HIV diagnosis | 2009 | 2010 | 2011 | 2012 | 2013 | 20 | 09-20 | | County | HSR |
|-----------------------|------|------|------|------|------|-----|----------------|-------------------|-------------------|-------------------|
| | No. | No. | No. | No. | No. | No. | % [†] | Rate [¥] | Rank [*] | Rank [^] |
| Region 1: | 2 | 3 | 2 | 1 | 0 | 8 | 0% | 2.2 | | 18 |
| Logan | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Morgan | 1 | 2 | 1 | 0 | 0 | 4 | 0% | 2.8 | 32 | |
| Phillips | 0 | 0 | 1 | 0 | 0 | 1 | 0% | 4.5 | 18 | |
| Sedgwick | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Washington | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Yuma | 1 | 1 | 0 | 1 | 0 | 3 | 0% | 6.0 | 11 | |
| Region 2: Larimer | 7 | 13 | 6 | 9 | 4 | 39 | 2% | 2.6 | 34 | 16 |
| Region 3: Douglas | 7 | 7 | 7 | 11 | 3 | 35 | 2% | 2.4 | 40 | 17 |
| Region 4: El Paso | 23 | 40 | 33 | 33 | 29 | 158 | 8% | 5.1 | 15 | 5 |
| Region 5: | 2 | 1 | 2 | 3 | 1 | 9 | 0% | 4.7 | | 6 |
| Cheyenne | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Elbert | 2 | 0 | 1 | 2 | 1 | 6 | 0% | 5.2 | 14 | |
| Lincoln | 0 | 1 | 1 | 0 | 0 | 2 | 0% | 6.7 | 8 | |
| Kit Carson | 0 | 0 | 0 | 1 | 0 | 1 | 0% | 2.6 | 34 | |
| Region 6: | 3 | 3 | 2 | 1 | 2 | 11 | 1% | 3.1 | | 13 |
| Baca | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Bent | 1 | 1 | 1 | 0 | 1 | 4 | 0% | 12.9 | 2 | |
| Crowley | 2 | 0 | 0 | 0 | 1 | 3 | 0% | 10.5 | 5 | |
| Huerfano | 0 | 1 | 0 | 0 | 0 | 1 | 0% | 2.9 | 30 | |
| Kiowa | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Las Animas | 0 | 1 | 1 | 0 | 0 | 2 | 0% | 2.6 | 34 | |
| Otero | 0 | 0 | 0 | 1 | 0 | 1 | 0% | 1.1 | 49 | |
| Prowers | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Region 7: Pueblo | 4 | 4 | 9 | 8 | 7 | 32 | 2% | 4.0 | 21 | 10 |
| Region 8: | 3 | 4 | 4 | 3 | 0 | 14 | 1% | 6.0 | | 4 |
| Alamosa | 2 | 2 | 0 | 1 | 0 | 5 | 0% | 6.4 | 10 | |
| Conejos | 1 | 1 | 1 | 1 | 0 | 4 | 0% | 9.7 | 6 | |
| Costilla | 0 | 0 | 2 | 0 | 0 | 2 | 0% | 11.2 | 3 | |
| Mineral | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Rio Grande | 0 | 0 | 1 | 1 | 0 | 2 | 0% | 3.3 | 25 | |
| Saguache | 0 | 1 | 0 | 0 | 0 | 1 | 0% | 3.2 | 26 | |
| Region 9: | 4 | 1 | 0 | 2 | 1 | 8 | 0% | 1.7 | | 20 |
| Archuleta | 0 | 0 | 0 | 1 | 0 | 1 | 0% | 1.7 | 43 | |
| Dolores | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| La Plata | 2 | 1 | 0 | 1 | 1 | 5 | 0% | 1.9 | 42 | |
| Montezuma | 2 | 0 | 0 | 0 | 0 | 2 | 0% | 1.6 | 45 | |
| San Juan | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |

[†] Percent of HSRs' new HIV disease diagnoses (2009-2013)

[¥] Health Statistics Region HIV infection rates per 100,000 population is calculated by dividing each region's sum of HIV diagnoses by the region's total population.

^{*} Counties ranked by HIV infection rate per 100,000 population

[^] Health Statistics Regions ranked by HIV infection rate per 100,000 population

^{‡ 2008-2010} population updated estimate from the State Demographer's Office and 2011 -2012 Census estimate used in calculating the rates

Table 4. HIV Diagnoses by Health Statistics Region and County, continued

| | | | | | IIV Dise | | | | | |
|-----------------------|------|------|------|------|----------|-------|----------------|------|-------------------|-------------------|
| Year of HIV diagnosis | 2009 | 2010 | 2011 | 2012 | 2013 | 20 | 09-201 | .3 | County | HSR |
| | No. | No. | No. | No. | No. | No. | % [†] | Rate | Rank [*] | Rank [^] |
| Region 10: | 2 | 2 | 1 | 0 | 2 | 7 | 0% | 1.4 | | 21 |
| Delta | 1 | 0 | 1 | 0 | 0 | 2 | 0% | 1.3 | 48 | |
| Gunnison | 0 | 1 | 0 | 0 | 1 | 2 | 0% | 2.6 | 34 | |
| Hinsdale | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Montrose | 1 | 1 | 0 | 0 | 0 | 2 | 0% | 1.0 | 50 | |
| Ouray | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| San Miguel | 0 | 0 | 0 | 0 | 1 | 1 | 0% | 2.7 | 33 | |
| Region 11: | 1 | 3 | 0 | 1 | 0 | 5 | 0% | 2.2 | | 18 |
| Jackson | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Moffat | 1 | 0 | 0 | 0 | 0 | 1 | 0% | 1.5 | 46 | |
| Rio Blanco | 0 | 0 | 0 | 1 | 0 | 1 | 0% | 3.1 | 29 | |
| Routt | 0 | 3 | 0 | 0 | 0 | 3 | 0% | 2.6 | 34 | |
| Region 12: | 5 | 9 | 4 | 10 | 3 | 31 | 2% | 3.7 | | 11 |
| Eagle | 2 | 3 | 2 | 5 | 0 | 12 | 1% | 4.7 | 17 | |
| Garfield | 2 | 0 | 1 | 4 | 2 | 9 | 0% | 3.2 | 26 | |
| Grand | 0 | 1 | 0 | 0 | 0 | 1 | 0% | 1.4 | 47 | |
| Pitkin | 0 | 2 | 0 | 0 | 0 | 2 | 0% | 2.3 | 41 | |
| Summit | 1 | 3 | 1 | 1 | 1 | 7 | 0% | 5.0 | 16 | |
| Region 13: | 7 | 5 | 2 | 2 | 0 | 16 | 1% | 4.2 | | 7 |
| Chaffee | 1 | 2 | 1 | 1 | 0 | 5 | 0% | 5.6 | 12 | |
| Custer | 0 | 0 | 0 | 0 | 0 | 0 | 0% | 0.0 | 51 | |
| Fremont | 6 | 2 | 0 | 1 | 0 | 9 | 0% | 3.8 | 22 | |
| Lake | 0 | 1 | 1 | 0 | 0 | 2 | 0% | 5.5 | 13 | |
| Region 14: Adams | 62 | 49 | 43 | 45 | 40 | 239 | 13% | 10.8 | 4 | 2 |
| Region 15: Arapahoe | 42 | 64 | 52 | 60 | 56 | 274 | 15% | 9.5 | 7 | 3 |
| Region 16: | 25 | 13 | 11 | 13 | 12 | 74 | 4% | 4.2 | | 7 |
| Boulder | 22 | 10 | 10 | 12 | 11 | 65 | 3% | 4.4 | 19 | |
| Broomfield | 3 | 3 | 1 | 1 | 1 | 9 | 0% | 3.2 | 26 | |
| Region 17: | 0 | 2 | 2 | 3 | 1 | 8 | 0% | 3.0 | | 14 |
| Clear Creek | 0 | 2 | 0 | 1 | 0 | 3 | 0% | 6.6 | 9 | |
| Gilpin | 0 | 0 | 0 | 1 | 0 | 1 | 0% | 3.7 | 23 | |
| Park | 0 | 0 | 1 | 1 | 0 | 2 | 0% | 2.5 | 39 | |
| Teller | 0 | 0 | 1 | 0 | 1 | 2 | 0% | 1.7 | 43 | |
| Region 18: Weld | 7 | 8 | 10 | 5 | 7 | 37 | 2% | 2.9 | 30 | 15 |
| Region 19: Mesa | 8 | 4 | 1 | 9 | 5 | 27 | 1% | 3.7 | 23 | 11 |
| Region 20: Denver | 159 | 174 | 156 | 146 | 107 | 742 | 39% | 24.5 | 1 | 1 |
| Region 21: Jefferson | 15 | 21 | 31 | 23 | 22 | 112 | 6% | 4.2 | 20 | 7 |
| STATEWIDE TOTAL | 388 | 430 | 378 | 388 | 302 | 1,886 | 100% | 7.5 | | |

[†] Percent of HSRs' new HIV diagnoses (2009-2013)

^{*} Counties ranked by HIV infection rate per 100,000 population

[^] Health Statistics Regions ranked by HIV infection rate per 100,000 population

^{‡ 2008-2010} population updated estimate from the State Demographer's Office and 2011 -2012. Census estimate used in calculating the rates

Table 5. Cumulative HIV/AIDS case counts and deaths by most recent county and Health Statistics Region (HSR) before death, Colorado (reported as of 12/31/13)

| Statistics Region (HS | Cumulative | | aths | | | , ned Livi | ng |
|-----------------------|------------|-----|------------|-----|------|---------------|---------|
| | Cases | N | % * | HIV | AIDS | Total | Total % |
| Region 1: | 72 | 28 | 39% | 20 | 24 | 44 | 0.3% |
| Logan | 17 | 8 | 47% | 1 | 8 | 9 | 0.1% |
| Morgan | 34 | 15 | 44% | 12 | 7 | 19 | 0.2% |
| Phillips | 5 | 3 | 60% | 0 | 2 | 2 | 0.0% |
| Sedgwick | 1 | 0 | 0% | 1 | 0 | 1 | 0.0% |
| Washington | 3 | 0 | 0% | 2 | 1 | 3 | 0.0% |
| Yuma | 12 | 2 | 17% | 4 | 6 | 10 | 0.1% |
| Region 2: Larimer | 320 | 83 | 26% | 120 | 117 | 237 | 1.9% |
| Region 3: Douglas | 204 | 36 | 18% | 83 | 85 | 168 | 1.3% |
| Region 4: El Paso | 1340 | 432 | 32% | 510 | 398 | 908 | 7.2% |
| Region 5: | 37 | 8 | 22% | 17 | 12 | 29 | 0.2% |
| Cheyenne | 1 | 0 | 0% | 0 | 1 | 1 | 0.0% |
| Elbert | 26 | 5 | 19% | 12 | 9 | 21 | 0.2% |
| Lincoln | 5 | 1 | 20% | 3 | 1 | 4 | 0.0% |
| Kit Carson | 5 | 2 | 40% | 2 | 1 | 3 | 0.0% |
| Region 6: | 88 | 31 | 35% | 30 | 27 | 57 | 0.5% |
| Baca | 2 | 1 | 50% | 0 | 1 | 1 | 0.0% |
| Bent | 5 | 3 | 60% | 2 | 0 | 2 | 0.0% |
| Crowley | 13 | 0 | 0% | 9 | 4 | 13 | 0.1% |
| Huerfano | 9 | 3 | 33% | 2 | 4 | 6 | 0.0% |
| Kiowa | 0 | 0 | | 0 | 0 | 0 | 0.0% |
| Las Animas | 28 | 14 | 50% | 9 | 5 | 14 | 0.1% |
| Otero | 19 | 6 | 32% | 6 | 7 | 13 | 0.1% |
| Prowers | 12 | 4 | 33% | 2 | 6 | 8 | 0.1% |
| Region 7: Pueblo | 278 | 100 | 36% | 89 | 89 | 178 | 1.4% |
| Region 8: | 59 | 25 | 42% | 14 | 20 | 34 | 0.3% |
| Alamosa | 23 | 12 | 52% | 4 | 7 | 11 | 0.1% |
| Conejos | 6 | 2 | 33% | 1 | 3 | 4 | 0.0% |
| Costilla | 9 | 4 | 44% | 4 | 1 | 5 | 0.0% |
| Mineral | 0 | 0 | | 0 | 0 | 0 | 0.0% |
| Rio Grande | 12 | 3 | 25% | 4 | 5 | 9 | 0.1% |
| Saguache | 9 | 4 | 44% | 1 | 4 | 5 | 0.0% |
| Region 9: | 91 | 23 | 25% | 37 | 31 | 68 | 0.5% |
| Archuleta | 9 | 1 | 11% | 4 | 4 | 8 | 0.1% |
| Dolores | 1 | 0 | 0% | 0 | 1 | 1 | 0.0% |
| La Plata | 60 | 16 | 27% | 25 | 19 | 44 | 0.3% |
| Montezuma | 17 | 6 | 35% | 6 | 5 | 11 | 0.1% |
| San Juan | 4 | 0 | 0% | 2 | 2 | 4 | 0.0% |
| Region 10: | 68 | 23 | 34% | 21 | 24 | 45 | 0.4% |
| Delta | 20 | 6 | 30% | 6 | 8 | 14 | 0.1% |
| Gunnison | 12 | 3 | 25% | 4 | 5 | 9 | 0.1% |
| Hinsdale | 4 | 2 | 50% | 2 | 0 | 2 | 0.0% |
| Montrose | 21 | 7 | 33% | 5 | 9 | 14 | 0.1% |
| Ouray | 2 | 1 | 50% | 1 | 0 | 1 | 0.0% |
| San Miguel | 9 | 4 | 44% | 3 | 2 | 5 | 0.0% |

Due to delays in reporting, data from recent years are incomplete.

^{*} Percent of county cases who have died (row %).

[^] Percent of total presumed living cases in Colorado (column %).

Table 5. Cumulative HIV/AIDS case counts and deaths by most recent county and Health Statistics Region (HSR) before death, continued

| | Cumulative | Dea | ths | | Presun | ned Livi | ng |
|----------------------|------------|-------|------------|-------|--------|----------|---------|
| | Cases | N | % * | HIV | AIDS | Total | Total % |
| Region 11: | 41 | 12 | 29% | 13 | 16 | 29 | 0.2% |
| Jackson | 2 | 0 | 0% | 0 | 2 | 2 | 0.0% |
| Moffat | 12 | 4 | 33% | 3 | 5 | 8 | 0.1% |
| Rio Blanco | 5 | 1 | 20% | 1 | 3 | 4 | 0.0% |
| Routt | 22 | 7 | 32% | 9 | 6 | 15 | 0.1% |
| Region 12: | 280 | 59 | 21% | 95 | 126 | 221 | 1.8% |
| Eagle | 90 | 12 | 13% | 32 | 46 | 78 | 0.6% |
| Garfield | 63 | 12 | 19% | 28 | 23 | 51 | 0.4% |
| Grand | 21 | 8 | 38% | 6 | 7 | 13 | 0.1% |
| Pitkin | 42 | 11 | 26% | 11 | 20 | 31 | 0.2% |
| Summit | 64 | 16 | 25% | 18 | 30 | 48 | 0.4% |
| Region 13: | 226 | 73 | 32% | 63 | 90 | 153 | 1.2% |
| Chaffee | 14 | 7 | 50% | 2 | 5 | 7 | 0.1% |
| Custer | 2 | 0 | 0% | 0 | 2 | 2 | 0.0% |
| Fremont | 204 | 64 | 31% | 59 | 81 | 140 | 1.1% |
| Lake | 6 | 2 | 33% | 2 | 2 | 4 | 0.0% |
| Region 14: Adams | 1231 | 299 | 24% | 453 | 479 | 932 | 7.4% |
| Region 15: Arapahoe | 1820 | 447 | 25% | 730 | 643 | 1373 | 10.9% |
| Region 16: | 702 | 183 | 26% | 292 | 227 | 519 | 4.1% |
| Boulder | 673 | 182 | 27% | 275 | 216 | 491 | 3.9% |
| Broomfield | 29 | 1 | 3% | 17 | 11 | 28 | 0.2% |
| Region 17: | 82 | 27 | 33% | 20 | 35 | 55 | 0.4% |
| Clear Creek | 30 | 8 | 27% | 8 | 14 | 22 | 0.2% |
| Gilpin | 14 | 9 | 64% | 3 | 2 | 5 | 0.0% |
| Park | 22 | 5 | 23% | 5 | 12 | 17 | 0.1% |
| Teller | 16 | 5 | 31% | 4 | 7 | 11 | 0.1% |
| Region 18: Weld | 258 | 84 | 33% | 84 | 90 | 174 | 1.4% |
| Region 19: Mesa | 179 | 45 | 25% | 68 | 66 | 134 | 1.1% |
| Region 20: Denver | 10192 | 3559 | 35% | 3779 | 2854 | 6633 | 52.5% |
| Region 21: Jefferson | 970 | 352 | 36% | 333 | 285 | 618 | 4.9% |
| Unknown | 18 | 4 | 22% | 12 | 2 | 14 | 0.1% |
| STATEWIDE TOTAL | 18,556 | 5,933 | 32% | 6,883 | 5,740 | 12,623 | 100.0% |

^{*}Percent of county cases who have died (row %).

Presumed Colorado residence based on most recent data available.

No exclusions based on HIV lab tests.

[^] Percent of total presumed living cases in Colorado (column %).

ACKNOWLEDGEMENTS AND CONTACT INFORMATION

We wish to acknowledge the contribution of persons with HIV, HIV health providers, our local health jurisdiction partners, the medical laboratories, and community groups. Publication of this report would not have been possible without their cooperation, dedication, and hard work. These data are used to support the allocation of HIV prevention and care resources, to conduct program planning and evaluation, and to educate the public about the HIV epidemic in Colorado.

Sexually Transmitted Infections/HIV Surveillance Section Disease Control and Environmental Epidemiology Division Colorado Department of Public Health and Environment 4300 Cherry Creek Drive South, A-3 Denver, CO 80246-1530

Tel: (303) 692-2700 Fax: (303) 782-5393

